CY1112682T1 - Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων - Google Patents

Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων

Info

Publication number
CY1112682T1
CY1112682T1 CY20121100338T CY121100338T CY1112682T1 CY 1112682 T1 CY1112682 T1 CY 1112682T1 CY 20121100338 T CY20121100338 T CY 20121100338T CY 121100338 T CY121100338 T CY 121100338T CY 1112682 T1 CY1112682 T1 CY 1112682T1
Authority
CY
Cyprus
Prior art keywords
active
medical uses
protein conjugates
active portions
medical
Prior art date
Application number
CY20121100338T
Other languages
Greek (el)
English (en)
Inventor
Valter Altarocca
Anna R Pezzotti
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1112682T1 publication Critical patent/CY1112682T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
CY20121100338T 2003-05-13 2012-04-04 Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων CY1112682T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101326 2003-05-13
EP04739182A EP1622939B1 (en) 2003-05-13 2004-05-11 Active variants of the il-18 binding protein and medical uses thereof

Publications (1)

Publication Number Publication Date
CY1112682T1 true CY1112682T1 (el) 2016-02-10

Family

ID=33442815

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100338T CY1112682T1 (el) 2003-05-13 2012-04-04 Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων

Country Status (16)

Country Link
US (2) US20080076708A1 (hr)
EP (1) EP1622939B1 (hr)
JP (1) JP5074030B2 (hr)
AT (1) ATE549353T1 (hr)
AU (1) AU2004238524B2 (hr)
CA (1) CA2524403C (hr)
CY (1) CY1112682T1 (hr)
DK (1) DK1622939T3 (hr)
ES (1) ES2384241T3 (hr)
HR (1) HRP20120246T1 (hr)
IL (1) IL171914A (hr)
NO (1) NO338682B1 (hr)
PL (1) PL1622939T3 (hr)
PT (1) PT1622939E (hr)
SI (1) SI1622939T1 (hr)
WO (1) WO2004101617A1 (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
PL1601776T4 (pl) * 2003-03-11 2009-05-29 Merck Serono Sa Wektory ekspresyjne zawierające promotor mCMV-IE2
ATE484591T1 (de) * 2003-10-21 2010-10-15 Merck Serono Sa Minimale dna sequenz, die als chromatin-isolator wirkt, und deren verwendung für die protein- expression
PL1689777T3 (pl) * 2003-11-05 2007-09-28 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
SI1720979T1 (sl) 2004-03-01 2007-12-31 Ares Trading Sa Uporaba medija za celiäśno kulturo brez seruma zaizdelavo il-18bp pri celicah sesalcev
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
AU2005259269B2 (en) * 2004-06-29 2010-12-09 Ares Trading S.A. Process for the purification of IL-18 binding protein
DK2267024T3 (da) * 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
SI1888100T1 (sl) 2005-06-03 2012-01-31 Merck Serono Sa Uporaba izooblik il-18pb za zdravljenje in/ali prepreäśevanje nevroloĺ kih vnetnih bolezni
CA2610804C (en) 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
CN103228290A (zh) 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
UA125204C2 (uk) 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
MY194040A (en) 2015-03-05 2022-11-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CN111315395A (zh) * 2017-09-06 2020-06-19 耶鲁大学 白细胞介素-18变体和使用方法
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
JP4216950B2 (ja) * 1998-09-01 2009-01-28 株式会社林原生物化学研究所 インターロイキン−１８結合蛋白質
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
WO2001085201A2 (en) 2000-05-05 2001-11-15 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
CN1326562C (zh) 2001-01-29 2007-07-18 应用研究***Ars股份公司 Il－18抑制剂制造治疗和/或预防心脏病的药物的应用
BR0210904A (pt) 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
UA80396C2 (en) 2001-05-25 2007-09-25 Ares Trading Sa Use of il-18 inhibitors for treating or traumatic head injury
DK1434597T3 (da) 2001-10-11 2012-02-27 Merck Serono Sa Anvendelse af gp130-aktivatorer ved diabetisk neuropati
PL1601776T4 (pl) * 2003-03-11 2009-05-29 Merck Serono Sa Wektory ekspresyjne zawierające promotor mCMV-IE2
ATE484591T1 (de) * 2003-10-21 2010-10-15 Merck Serono Sa Minimale dna sequenz, die als chromatin-isolator wirkt, und deren verwendung für die protein- expression
PL1689777T3 (pl) * 2003-11-05 2007-09-28 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
SI1720979T1 (sl) * 2004-03-01 2007-12-31 Ares Trading Sa Uporaba medija za celiäśno kulturo brez seruma zaizdelavo il-18bp pri celicah sesalcev
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
AU2005259269B2 (en) * 2004-06-29 2010-12-09 Ares Trading S.A. Process for the purification of IL-18 binding protein
DK2267024T3 (da) * 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
CA2610804C (en) * 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein

Also Published As

Publication number Publication date
US20110189131A1 (en) 2011-08-04
AU2004238524B2 (en) 2011-06-23
WO2004101617A1 (en) 2004-11-25
AU2004238524A1 (en) 2004-11-25
CA2524403C (en) 2013-07-09
HRP20120246T1 (hr) 2012-04-30
EP1622939B1 (en) 2012-03-14
IL171914A (en) 2013-05-30
EP1622939A1 (en) 2006-02-08
NO338682B1 (no) 2016-09-26
PL1622939T3 (pl) 2012-08-31
PT1622939E (pt) 2012-03-28
NO20055838L (no) 2006-02-13
US20080076708A1 (en) 2008-03-27
JP5074030B2 (ja) 2012-11-14
JP2007535903A (ja) 2007-12-13
CA2524403A1 (en) 2004-11-25
SI1622939T1 (sl) 2012-06-29
ES2384241T3 (es) 2012-07-02
NO20055838D0 (no) 2005-12-08
DK1622939T3 (da) 2012-04-10
ATE549353T1 (de) 2012-03-15
IL171914A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
CY1112682T1 (el) Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων
CY1118038T1 (el) Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος
CY1115414T1 (el) Παραγωγα υποκατεστημενου 1-3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
CY1107440T1 (el) Ενωσεις αρυλουριας εν συνδυασμω με αλλα κυτταροστατικα ή κυτταροτοξικα μεσα για τη θεραπεια ανθρωπινων καρκινων
CY1107419T1 (el) Προφαρμακα αντι-ιικων μεσων απο πιπεραζινη και υποκατεστημενη πιπεριδινη
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
NO20044039L (no) Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider.
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CY1105008T1 (el) Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης
SE0301653D0 (sv) Novel compounds
ATE509949T1 (de) Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CY1109465T1 (el) Νεες φαρμακευτικες φαρμακοτεχνικες μορφες μονταφινιλης
LU92202I2 (fr) Aflibercept
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
BRPI0411485A (pt) peptìdeo derivado de rasgap para matar seletivamente células cancerosas
NO20063293L (no) Farmasoytiske forbindelser
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
DE602006020155D1 (de) Pharmazeutische wundheilungs-zusammensetzungen in ren und natriumhyaluronat
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
CY1110499T1 (el) Παρασκευασματα γελης 4-υδροξυ ταμοξιφενης
BRPI0410638A (pt) derivados de azitromicina
ATE464896T1 (de) Zubereitung enthaltend oxidierte flavonoid- derivate